T1	Participants 39 71	patients with serious infections
T2	Participants 252 328	patients with serious infections for whom an aminoglycoside seemed warranted
T3	Participants 330 402	Exclusion criteria were neutropenia or severely impaired renal function.
T4	Participants 403 429	123 patients were enrolled
T5	Participants 431 567	For efficacy analysis only those patients were considered in whom treatment with the aminoglycoside was not stopped within 72 h (n = 67)
T6	Participants 569 700	toxicity was analysed on patients receiving aminoglycosides for more than 48 h and not using other nephrotoxic medication (n = 85).
T7	Participants 939 993	Baseline characteristics were comparable in both arms.
